- Home
- TDUP vs MNMD Comparison
TDUP vs MNMD Comparison
Compare TDUP & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | MNMD |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 960.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TDUP | MNMD |
|---|---|---|
| Price | $7.53 | $12.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $12.50 | ★ $25.78 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $298,376,000.00 | N/A |
| Revenue This Year | $20.94 | N/A |
| Revenue Next Year | $11.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.65 | N/A |
| 52 Week Low | $1.21 | $4.70 |
| 52 Week High | $12.28 | $14.43 |
Technical Indicators
Market Signals| Indicator | TDUP | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 54.32 |
| Support Level | $7.57 | $12.00 |
| Resistance Level | $7.97 | $13.15 |
| Average True Range (ATR) | 0.42 | 0.67 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 17.45 | 44.24 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).